How to Prevent Migraine with Aura
For episodic migraine with aura, initiate preventive therapy with first-line agents: propranolol (80-160 mg daily), topiramate (50-100 mg daily), candesartan (16-32 mg daily), or amitriptyline (10-100 mg nightly), with the critical caveat that combined hormonal contraceptives are absolutely contraindicated in women with migraine with aura due to increased stroke risk. 1
When to Start Prevention
Preventive therapy is indicated when you have:
- ≥2 attacks per month causing disability for ≥3 days 2
- Failure of or contraindication to acute treatments
- Use of abortive medications more than twice weekly
- Uncommon migraine conditions including hemiplegic migraine, prolonged aura, or migrainous infarction 2
First-Line Preventive Medications
The 2021 Nature Reviews Neurology guidelines 1 and 2025 ACP guidelines 3 establish these as first-line options:
Beta-Blockers
- Propranolol: 80-160 mg daily (long-acting formulation)
- Metoprolol: 50-100 mg twice daily or 200 mg modified-release once daily
- Atenolol: 25-100 mg twice daily
- Timolol: 20-30 mg daily
Contraindications: Asthma, cardiac failure, Raynaud disease, atrioventricular block, depression
Anticonvulsants
- Topiramate: 50-100 mg daily (particularly beneficial if obesity is present) 1
- Valproate: 600-1500 mg daily
Critical contraindication: Valproate is absolutely contraindicated in women of childbearing potential due to teratogenic effects 1
Angiotensin II-Receptor Blocker
- Candesartan: 16-32 mg daily 1
Tricyclic Antidepressant
- Amitriptyline: 10-100 mg nightly (especially useful with comorbid depression or sleep disturbances) 1
Second-Line Options
If first-line agents fail or are not tolerated:
- Flunarizine: 5-10 mg daily (contraindicated in Parkinsonism, depression) 1
Third-Line Options (After 2-3 First-Line Failures)
- CGRP monoclonal antibodies: Erenumab (70-140 mg subcutaneous monthly), fremanezumab (225 mg monthly or 675 mg quarterly) 1, 3
- OnabotulinumtoxinA: 155-195 units every 12 weeks (for chronic migraine only, NOT episodic migraine) 1, 4
- Atogepant (CGRP antagonist-gepant) 3, 4
Aura-Specific Considerations
Evidence for Lamotrigine in Migraine with Aura
While not included in standard first-line recommendations, lamotrigine shows promise specifically for reducing aura frequency in patients whose burden is dominated by aura symptoms. A 2026 study demonstrated 79.7% mean reduction in monthly aura days at an average dose of 149.6 mg, with 85.2% response rate 5. Lamotrigine, daily aspirin, and flunarizine have specific evidence for aura prevention 6, 7.
However, the 2021 guidelines note that prophylactic treatments for migraine with aura are generally the same as those for migraine without aura, as there are very few randomized trials specifically dedicated to migraine with aura 8.
Critical Safety Warning for Women
Combined hormonal contraceptives are absolutely contraindicated in women with migraine with aura regardless of menstrual association, due to significantly increased stroke risk 1. Migraine with aura itself carries a modestly increased risk of ischemic stroke 1, 6, 8.
Implementation Strategy
Start low, titrate slowly: Begin with low doses and increase gradually until benefits appear without adverse effects 2
Allow adequate trial period: Clinical benefits may take 2-3 months to manifest 2
Monitor with headache calendars: Track attack frequency, severity, duration, disability, and medication use 1
Evaluate response at 2-3 months, then every 6-12 months 1
Target outcome: ≥50% reduction in monthly migraine days 3
Consider tapering after stability: After a period of sustained improvement, consider gradual discontinuation 2
Common Pitfalls to Avoid
- Don't use gabapentin for episodic migraine prevention—it is not recommended 4
- Don't prescribe onabotulinumtoxinA for episodic migraine—it's only for chronic migraine (≥15 headache days/month) 1, 4
- Don't overlook medication overuse: Using acute medications >2 days/week increases risk of transformation to chronic migraine 1
- Don't ignore comorbidities: Depression, anxiety, obesity, and sleep disturbances influence both drug choice and outcomes 1
Modifiable Risk Factors
Address these to prevent transformation to chronic migraine:
- High headache frequency
- Inadequate acute treatment
- Overuse of acute medications (>2 days/week)
- Depression and anxiety
- Obesity 1